Catalent completed the acquisition of MaSTherCell Global for $315m.

Catalent, an integrated services, superior delivery technologies, and manufacturing solutions provider for pharmaceutical industry, completed the acquisition of MaSTherCell Global, a technology-focused cell and gene therapy contract development and manufacturing organization, from Great Point Partners, SFPI-FPIM and biotechnology company Orgenesis for $315m. "We are excited to join the industry-leading team at Catalent and work together to scale-up our business. This combination will strengthen our service offering to our customers and, in the end, benefit patients who need innovative life-saving therapies," Darren Head, MaSTherCell CEO.